Asset Impairment, Exit, and Restructuring Costs

9 Months Ended

Sep. 30, 2025

Restructuring, Settlement and Impairment Provisions [Abstract]

Asset Impairment, Exit, and Restructuring Costs

Asset Impairment, Exit, and Restructuring Costs

The following table sets forth the charges for the three and nine months ended September 30, 2025 and 2024 (in millions).

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Restructuring and exit costs (1)	$	73	$	—	$	237	$	15
Impairment charge - goodwill and other intangible assets (2)	173		43		173		43
Impairment charge - other long-lived assets (3)	—		464		11		474
Total asset impairment, exit, and restructuring costs	$	246	$	507	$	421	$	532

(1)On February 4, 2025, the Company announced targeted actions expected to deliver in excess of $500 million of cost savings by fiscal 2029. These include cost optimization and portfolio simplification initiatives designed to help the Company achieve cost efficiencies. Charges associated with these actions, as well as similar initiatives in prior periods, are reflected as restructuring charges. The three months ended September 30, 2025 included restructuring charges (primarily impairment of long-lived assets and employee termination benefits) of $67 million, $5 million and $1 million within the Nutrition segment, Ag Services and Oilseeds segment, and Corporate, respectively, presented as specified items. The nine months ended September 30, 2025 included restructuring charges (primarily impairment of long-lived assets, impairment of intangible assets, and employee termination benefits) of $190 million, $34 million, $5 million, and $8 million within the Nutrition segment, the Ag Services and Oilseeds segment, the Carbohydrate Solutions segment, and Corporate, respectively, presented as specified items. The nine months ended September 30, 2024 included restructuring charges of $3 million and $12 million within the Nutrition segment and Corporate, respectively, both presented as specified items.

(2)During the three and nine months ended September 30, 2025, the Company recognized an impairment charge of $173 million, related to previously capitalized internal-use software, within Corporate, presented as a specified item. During the three and nine months ended September 30, 2024, the Company recognized an impairment charge of $43 million related to certain discontinued trademarks, within Nutrition segment, presented as a specified item.

(3)During the nine months ended September 30, 2025, the Company recorded an impairment of $11 million related to a certain long-lived asset within the Nutrition segment, presented as a specified item. During the three and nine months ended September 30, 2024, the Company recorded an impairment of $461 million related to the Company’s investment in Wilmar, within the Ag Services and Oilseeds segment, presented as a specified item.